Hospitalisation rates and characteristics for adult and childhood immunoglobulin A vasculitis in Western Australia.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
04 2019
Historique:
received: 07 05 2018
revised: 19 07 2018
accepted: 24 07 2018
pubmed: 10 8 2018
medline: 9 1 2020
entrez: 10 8 2018
Statut: ppublish

Résumé

Immunoglobulin A vasculitis (IgAV) is a systemic small-vessel vasculitis of unknown aetiology. Although commonest in children, onset in adulthood is not unusual. As Australian data are lacking, we investigated longitudinal hospitalisation rates and characteristics for both adult and paediatric IgAV patients in Western Australia (WA). Data were extracted from a state-wide register for all first hospital contacts in WA between 1980 and 2015 for patients with a primary diagnosis of IgAV. Paediatric cases were defined as those <20 years and compared with adult cases for admission rates per 100 000, demographics, complications, length of stay (LOS) and readmission rates. The study cohort included 476 children (median age 5 years; interquartile range (IQR) 3-7) and 144 adults (median age 50 years; IQR 36-77). Childhood admission rates declined from 3.85 to 0.31 over time (P < 0.001) but age at admission and LOS remained unchanged. For adults, admission rates declined from 0.40 to 0.17 (P = 0.02) while age at admission (43 vs 63 years, P = 0.01) and LOS (5 vs 9 days, P = 0.02) increased. More adults had renal (11.8 vs 1.3%, P < 0.01), intestinal (3.5 vs 0.8%, P = 0.04) and infectious (14.6% vs 5.3%, P < 0.01) complications. Readmission was more frequent in childhood cases (23.1% vs 7.6%, P < 0.05) occurring mostly within 30 days of discharge. Hospitalisation rates for adults with IgAV now nearly equal those in children as adult IgAV leads to more complications. The sharp decline in childhood IgAV admissions suggests that confidence to manage children with IgAV outside the hospital setting has increased.

Sections du résumé

BACKGROUND
Immunoglobulin A vasculitis (IgAV) is a systemic small-vessel vasculitis of unknown aetiology. Although commonest in children, onset in adulthood is not unusual.
AIM
As Australian data are lacking, we investigated longitudinal hospitalisation rates and characteristics for both adult and paediatric IgAV patients in Western Australia (WA).
METHODS
Data were extracted from a state-wide register for all first hospital contacts in WA between 1980 and 2015 for patients with a primary diagnosis of IgAV. Paediatric cases were defined as those <20 years and compared with adult cases for admission rates per 100 000, demographics, complications, length of stay (LOS) and readmission rates.
RESULTS
The study cohort included 476 children (median age 5 years; interquartile range (IQR) 3-7) and 144 adults (median age 50 years; IQR 36-77). Childhood admission rates declined from 3.85 to 0.31 over time (P < 0.001) but age at admission and LOS remained unchanged. For adults, admission rates declined from 0.40 to 0.17 (P = 0.02) while age at admission (43 vs 63 years, P = 0.01) and LOS (5 vs 9 days, P = 0.02) increased. More adults had renal (11.8 vs 1.3%, P < 0.01), intestinal (3.5 vs 0.8%, P = 0.04) and infectious (14.6% vs 5.3%, P < 0.01) complications. Readmission was more frequent in childhood cases (23.1% vs 7.6%, P < 0.05) occurring mostly within 30 days of discharge.
CONCLUSION
Hospitalisation rates for adults with IgAV now nearly equal those in children as adult IgAV leads to more complications. The sharp decline in childhood IgAV admissions suggests that confidence to manage children with IgAV outside the hospital setting has increased.

Identifiants

pubmed: 30091295
doi: 10.1111/imj.14065
doi:

Substances chimiques

Immunoglobulin A 0

Types de publication

Comparative Study Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

475-481

Subventions

Organisme : Arthritis Foundation of Western Australia
Pays : International

Informations de copyright

© 2018 Royal Australasian College of Physicians.

Auteurs

Johannes Nossent (J)

Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Rheumatology Group, School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

Warren Raymond (W)

Rheumatology Group, School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

Helen Keen (H)

Rheumatology Group, School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Department of Rheumatology, Fiona Stanley Hospital, Perth, Western Australia, Australia.

Charles Inderjeeth (C)

Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Rheumatology Group, School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

David B Preen (DB)

School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH